Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,763.96
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
103.23
(
-1.15%
)
Bitcoin
70,248.53
(
0.50%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: DewDiligence post# 97198

Thursday, 07/22/2010 9:01:05 AM

Thursday, July 22, 2010 9:01:05 AM

Post# of 257262
Re: Who's Who in All-Oral HCV Programs

I think we can now add ACHN to this list with the announcement of the NS5A inhibitor today. ACHN will also share with IDIX the important point of potentially having the only combo with the potential for QD dosing. Obviously, ACH-1625 does not work on all genotypes but the potential is there for ACH-2684 to do so.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now